D-Retro-Inverso Peptide Candidates for Inhibiting SAA Cardiac Amyloidosis
Andrew D. ChesneyiD, Lucy M. Coleman, Ulrich H. E. HansmanniD
Abstract
In a recent study of a mice model it was suggested that after myocardial infarction Serum Amyloid A (SAA) aggregates are formed that contribute to the long-term complications of the infarct, and that a similar mechanism may exist for humans. Motivated by this hypothesis we have designed four peptide candidates that may interfere with formation of SAA3 fibrils, and using all-atom molecular dynamics have evaluated their ability to destabilize SAA fibrils. As the lifetime of peptide drugs can be increased by replacing L-amino acids with their mirror D-amino acids, we have built the peptides from D-amino acids. We identify two of these peptides, DRI-R5S and DRI-H6A, as promising drug candidates.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Effect of Retro-inverse D-Amino Acid Aβ-peptides on Aβ- Fibril Formation
W. Xi, U. H. E. Hansmann·bioRxiv·Oct 31, 2018
- Modulating Transthyretin Fibril Stability with D-Retro-Inverso Peptides
Lucy M. Coleman, Ulrich H. E. Hansmann·Journal of Chemical Information and ModelingPeer-reviewed·Oct 27, 2026
- D-Retro Inverso (DRI) Amylin and the Stability of Amylin Fibrils
Preeti Pandey, Natalie N. M. Nguyen, Ulrich H. E. Hansmann·Journal of Chemical Theory and ComputationPeer-reviewed·Jul 15, 2020
- Podoplanin Positive Cell-derived Extracellular Vesicles Contribute to Cardiac Amyloidosis After Myocardial Infarction
Maria Cimini, Ulrich H. E. Hansmann, … Raj Kishore·Cell ReportsPeer-reviewed·Mar 1, 2025
- Stability of Human Serum Amyloid A Fibrils
W. Wang, U. H. E. Hansmann·bioRxiv·Sep 10, 2020
- Acute myocardial injury in mdx hearts ameliorated by ARB but not ACE inhibitor treatment
T. A. Meyers, J. A. Heitzman, D. Townsend·bioRxiv·Sep 11, 2019